Peddock Capital Advisors LLC Acquires New Stake in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN)

Peddock Capital Advisors LLC acquired a new stake in shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 2,512 shares of the biopharmaceutical company’s stock, valued at approximately $246,000.

Several other hedge funds and other institutional investors also recently bought and sold shares of ALXN. Nuveen Asset Management LLC increased its stake in shares of Alexion Pharmaceuticals by 57,650.8% during the second quarter. Nuveen Asset Management LLC now owns 3,637,144 shares of the biopharmaceutical company’s stock valued at $476,393,000 after acquiring an additional 3,630,846 shares during the period. Renaissance Technologies LLC increased its stake in shares of Alexion Pharmaceuticals by 104.9% during the second quarter. Renaissance Technologies LLC now owns 1,642,542 shares of the biopharmaceutical company’s stock valued at $215,140,000 after acquiring an additional 840,742 shares during the period. Swedbank increased its stake in shares of Alexion Pharmaceuticals by 95.5% during the second quarter. Swedbank now owns 1,429,397 shares of the biopharmaceutical company’s stock valued at $187,222,000 after acquiring an additional 698,096 shares during the period. Prudential Financial Inc. increased its stake in shares of Alexion Pharmaceuticals by 87.0% during the second quarter. Prudential Financial Inc. now owns 1,180,067 shares of the biopharmaceutical company’s stock valued at $154,565,000 after acquiring an additional 549,063 shares during the period. Finally, Vanguard Group Inc. increased its stake in shares of Alexion Pharmaceuticals by 1.3% during the second quarter. Vanguard Group Inc. now owns 16,649,126 shares of the biopharmaceutical company’s stock valued at $2,180,703,000 after acquiring an additional 211,960 shares during the period. Institutional investors and hedge funds own 93.24% of the company’s stock.

Alexion Pharmaceuticals stock traded down $4.57 during midday trading on Wednesday, reaching $100.24. The stock had a trading volume of 1,627,879 shares, compared to its average volume of 1,806,950. The firm’s fifty day simple moving average is $102.60 and its two-hundred day simple moving average is $119.37. Alexion Pharmaceuticals, Inc. has a twelve month low of $92.56 and a twelve month high of $141.86. The company has a debt-to-equity ratio of 0.26, a current ratio of 4.04 and a quick ratio of 3.56. The firm has a market cap of $22.25 billion, a price-to-earnings ratio of 14.14, a PEG ratio of 0.94 and a beta of 1.67.

Alexion Pharmaceuticals (NASDAQ:ALXN) last posted its quarterly earnings data on Wednesday, July 24th. The biopharmaceutical company reported $2.64 EPS for the quarter, topping analysts’ consensus estimates of $2.13 by $0.51. Alexion Pharmaceuticals had a net margin of 29.64% and a return on equity of 20.23%. The firm had revenue of $1.20 billion during the quarter, compared to analyst estimates of $1.18 billion. During the same quarter last year, the business posted $2.07 EPS. The company’s revenue was up 15.1% on a year-over-year basis. As a group, sell-side analysts predict that Alexion Pharmaceuticals, Inc. will post 9.05 EPS for the current fiscal year.

A number of analysts recently weighed in on the stock. Piper Jaffray Companies set a $180.00 target price on shares of Alexion Pharmaceuticals and gave the stock a “buy” rating in a report on Friday, September 6th. Stifel Nicolaus restated a “hold” rating on shares of Alexion Pharmaceuticals in a report on Friday, August 30th. JPMorgan Chase & Co. assumed coverage on shares of Alexion Pharmaceuticals in a report on Wednesday, July 31st. They set an “overweight” rating and a $172.00 target price for the company. BMO Capital Markets assumed coverage on shares of Alexion Pharmaceuticals in a report on Thursday, September 12th. They set an “outperform” rating and a $149.00 target price for the company. Finally, Citigroup set a $150.00 target price on shares of Alexion Pharmaceuticals and gave the stock a “buy” rating in a report on Friday, August 30th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and fourteen have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $159.76.

Alexion Pharmaceuticals Profile

Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and Soliris (eculizumab), a monoclonal antibody for the treatment of PNH, atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis.

See Also: Inverted Yield Curve

Want to see what other hedge funds are holding ALXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN).

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit